This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia). The report will be published at a forthcoming oncology conference in France. The case report describes two girls in France who were successfully treated with Bisantrene in 1984 and 1991. Both remain…
-
New director upbeat about Race Oncology’s growth prospects
New Race non-executive director Dr John Cullity has used his first interview to highlight the company’s growth potential.
-
Race appoints former Sanofi executive to the Board
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US, and he has consulted to the World Health Organization and the World Bank. “John brings an extraordinary wealth of technical…
-
Viralytics sale signals positive outlook for Race
In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million. As a former Director of Viralytics from 2008 – 2014, current Race Oncology Managing Director and CEO Peter Molloy said the result was an excellent outcome for its investors and…
-
Second Bisantrene Patent allowed in US
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof,” is the second of two Bisantrene patents filed in the US, Europe and…
-
Bisantrene Patent in US granted “Notice of Allowance”
A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof,” is one of two Bisantrene patents filed in the US, Europe and…
-
Race to present at J.P. Morgan Biotech Conference in US
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief Executive Peter Molloy will present on Monday 8 January, the opening day of the conference. “The J.P. Morgan Healthcare Conference is the largest and…
-
Soluta quia officia perferendis autem
Qui velit provident voluptatibus atque et est. Consequatur illum tenetur et minus tempora. Ut sunt autem accusantium. Itaque blanditiis fugit ipsam quos nulla harum eveniet Sit eos quasi explicabo Laboriosam Quam ut vel suscipit